Ribosomal Protein S6 Kinase 2 (RPS6KB2) is a Potential immunotherapeutic target for cancer with up-regulating pro-inflammatory cytokines

Abstract

Abstract Tumors are one of the main causes of death in people with illnesses. The therapy of tumors has evolved in recent years along with science and technology, and one such area of drug discovery is developing therapeutic targets for tumor treatment. Finding new pharmacological targets is increasingly urgent since tumor resistance affects how well current medications work. The chromosome 11 gene RPS6KB2 has been implicated in cell cycle regulation and has been found to express at much greater levels in tumor tissue. The association between RPS6KB2 and tumors raises the possibility that this gene could be a target for cancer treatment. Therefore, our study used data analysis and molecular biology methods to examine the potential involvement of RPS6KB2 in tumor therapy carefully. The data demonstrated that RPS6KB2, which has a poor prognosis, is aberrantly expressed in most tumors. Further data showed that RPS6KB2 is involved in tumor cell apoptosis and migration. RPS6KB2 also plays a role in tumor immune processes. We further verified the role of RPS6KB2 in liver cancer, and found that RPS6KB2 can up-regulate pro-inflammatory cytokines. In summary, RPS6KB2 maybe a novel therapeutic target.